NCT04807595 is a clinical trial of None (Observational study) in Breast Cancer, sponsored by AstraZeneca.

Who is sponsoring NCT04807595?

NCT04807595 is sponsored by AstraZeneca.

What drugs are being tested in NCT04807595?

Interventions in NCT04807595: None (Observational study).

What condition does NCT04807595 study?

NCT04807595 studies Breast Cancer.

Is NCT04807595 still recruiting?

NCT04807595 is currently completed. Last updated 6 March 2023.

Last reviewed 2023-03-06 · How we verify

NCT04807595

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Completed Last updated 6 March 2023

What this trial tests

trial testing None (Observational study) in Breast Cancer in 798 participants. Completed in 26 April 2022.

Timeline

28 May 2021

Primary endpoint
26 April 2022

26 April 2022

Quick facts

Lead sponsor	AstraZeneca
Status	Completed
Study type	OBSERVATIONAL
Enrollment	798
Start date	28 May 2021
Primary completion	26 April 2022
Estimated completion	26 April 2022
Sites	13 locations across France, Italy, Japan, United Kingdom, Germany, South Korea, Canada, Australia

Drugs / interventions tested

None (Observational study)

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a worldwide, multicenter, non-interventional, retrospective study of patient medical records from metastatic breast cancer (mBC) patients previously identified as human epidermal growth factor receptor 2 negative (HER2-neg), regardless of hormone status.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M, Porta FM, D'Ercole M, Pescia C, et al · · 2024 · cited 66× · PMID 37770765 · DOI 10.1007/s00428-023-03656-w
Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer.
Viale G, Basik M, Niikura N, Tokunaga E, et al · · 2023 · cited 65× · PMID 37562195 · DOI 10.1016/j.esmoop.2023.101615
Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.
Marchiò C, Criscitiello C, Scatena C, Santinelli A, et al · · 2023 · cited 14× · PMID 38180137 · DOI 10.32074/1591-951x-942
Applications and challenges of utilizing digital pathology and AI-enabled workflows in clinical trials.
Sebastian M, Batra H, Saini ML, Kearney S, et al · · 2026 · cited 1× · PMID 41631127 · DOI 10.1016/j.jpi.2025.100542

Verify or expand the search:

Other trials of None (Observational study)

Trials testing the same drug.

NCT07346768 — Evaluation of Anterior Neck Ultrasound in Predicting Difficult Airway in Obese Patients · not yet recruiting
NCT07141277 — GRANITE: Airsupra Effectiveness in the Real World · recruiting
NCT06222957 — The Effects of HER2 Receptor Signaling on Human Brown Fat Activity · recruiting
NCT06527872 — Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN · recruiting
NCT06607068 — Assessment of Taurine Concentration in Older Women With/Without Obesity And With/Without Type 2 Diabetes Mellitus · active not recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04807595 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 6 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04807595.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing